Lit Matters #1: Nitrofurantoin is Safe and Effective for Uncomplicated UTIs.

Nitrofurantoin remains a strong first-line choice for uncomplicated cystitis in healthy women, with a cleaner adverse-event profile than several commonly prescribed alternatives. For outpatient UTI treatment, antibiotic choice and duration both matter for rash, diarrhea, C. difficile risk, and microbiome disruption.

Antibiotic Choice in Uncomplicated UTI

• Nitrofurantoin safety signal: Nitrofurantoin served as the reference drug in a 1.16 million-patient comparison and was associated with fewer adverse events than fluoroquinolones, TMP-SMX, and many beta-lactams.
• Fluoroquinolone downside: Fluoroquinolones stood out for microbiome-related harm, including a marked increase in C. difficile diarrhea with a hazard ratio of 4.22 versus nitrofurantoin.
• TMP-SMX rash risk: TMP-SMX carried substantially more cutaneous reactions, with rash risk more than doubled compared with nitrofurantoin, while remaining a guideline-listed first-line option.
• Resistance landscape: Local susceptibility still matters: TMP-SMX resistance can approach 25%, while nitrofurantoin resistance is often under 2% for common uropathogens. We get into how that changes empiric choices in the episode.
• Duration and disruption: Longer antibiotic courses tracked with more microbiome-related adverse effects, reinforcing that uncomplicated cystitis treatment should stay as short as evidence allows.